Butterfly Network's Q2 Revenue Dips Amid Continued Losses
Ticker: BFLY · Form: 10-Q · Filed: Aug 1, 2025 · CIK: 1804176
| Field | Detail |
|---|---|
| Company | Butterfly Network, Inc. (BFLY) |
| Form Type | 10-Q |
| Filed Date | Aug 1, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Medical Devices, Ultrasound Technology, Quarterly Earnings, Revenue Decline, Net Loss, Accumulated Deficit, Healthcare Technology
Related Tickers: BFLY
TL;DR
**BFLY is still bleeding cash with revenue declining, avoid until they show a path to profitability.**
AI Summary
Butterfly Network, Inc. reported total revenue of $19.1 million for the three months ended June 30, 2025, a decrease from $20.5 million in the prior-year period. Product revenue declined to $12.3 million from $14.1 million, while Software and Other Services revenue increased to $6.8 million from $6.4 million. For the six months ended June 30, 2025, total revenue was $37.9 million, down from $40.1 million in the same period of 2024. The company continues to operate at a net loss, with a net loss of $38.2 million for the second quarter of 2025, compared to $42.5 million in Q2 2024. The accumulated deficit reached $1.1 billion as of June 30, 2025, up from $1.06 billion at December 31, 2024. Key business changes include a slight shift towards recurring software revenue, though product sales remain the dominant segment. Risks highlighted include continued operating losses and the need for additional capital, as evidenced by the accumulated deficit. The strategic outlook focuses on expanding its ultrasound technology, but profitability remains elusive.
Why It Matters
This filing reveals Butterfly Network's ongoing struggle to achieve profitability, with declining product revenue and persistent net losses. For investors, the accumulated deficit of $1.1 billion signals significant dilution risk and the potential need for further capital raises, impacting share value. Employees might face uncertainty given the company's financial performance and the competitive landscape in medical imaging. Customers could benefit from continued innovation in portable ultrasound, but the company's financial health could affect long-term support. In the broader market, this highlights the challenges for innovative medical device companies in scaling and monetizing their technology against established players like GE Healthcare and Philips.
Risk Assessment
Risk Level: high — The company reported an accumulated deficit of $1.1 billion as of June 30, 2025, and a net loss of $38.2 million for the second quarter of 2025. This consistent unprofitability and significant accumulated deficit indicate a high risk of needing additional capital, which could lead to further shareholder dilution.
Analyst Insight
Investors should exercise extreme caution and consider divesting or avoiding BFLY shares. The persistent net losses and declining revenue suggest fundamental business challenges that outweigh the potential for future growth in the near term.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $19.1M
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- -$38.2M
- eps
- N/A
- gross Margin
- N/A
- cash Position
- N/A
- revenue Growth
- -6.8%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product Revenue | $12.3M | -12.8% |
| Software and Other Services Revenue | $6.8M | +6.3% |
Key Numbers
- $19.1M — Total Revenue (Q2 2025) (Decreased from $20.5M in Q2 2024, indicating a 6.8% decline.)
- $12.3M — Product Revenue (Q2 2025) (Decreased from $14.1M in Q2 2024, showing a 12.8% drop in core sales.)
- $6.8M — Software and Other Services Revenue (Q2 2025) (Increased from $6.4M in Q2 2024, a modest 6.3% growth in recurring revenue.)
- $38.2M — Net Loss (Q2 2025) (Improved slightly from a $42.5M net loss in Q2 2024, but still a significant loss.)
- $1.1B — Accumulated Deficit (June 30, 2025) (Increased from $1.06B at December 31, 2024, highlighting ongoing unprofitability.)
Key Players & Entities
- Butterfly Network, Inc. (company) — filer of the 10-Q
- GE Healthcare (company) — competitor in medical imaging
- Philips (company) — competitor in medical imaging
- $19.1 million (dollar_amount) — total revenue for Q2 2025
- $20.5 million (dollar_amount) — total revenue for Q2 2024
- $1.1 billion (dollar_amount) — accumulated deficit as of June 30, 2025
- $38.2 million (dollar_amount) — net loss for Q2 2025
FAQ
What were Butterfly Network's total revenues for the second quarter of 2025?
Butterfly Network's total revenues for the three months ended June 30, 2025, were $19.1 million, a decrease from $20.5 million in the same period of 2024.
How did Butterfly Network's product revenue perform in Q2 2025?
Product revenue for Butterfly Network decreased to $12.3 million for the three months ended June 30, 2025, compared to $14.1 million in the prior-year quarter.
What was Butterfly Network's net loss for the second quarter of 2025?
Butterfly Network reported a net loss of $38.2 million for the three months ended June 30, 2025, which is an improvement from the $42.5 million net loss in Q2 2024.
What is Butterfly Network's accumulated deficit as of June 30, 2025?
As of June 30, 2025, Butterfly Network's accumulated deficit reached $1.1 billion, an increase from $1.06 billion reported at December 31, 2024.
Did Butterfly Network's software and services revenue grow in Q2 2025?
Yes, Butterfly Network's Software and Other Services revenue increased to $6.8 million for the three months ended June 30, 2025, up from $6.4 million in the same period of 2024.
What are the primary risks for investors in Butterfly Network?
Primary risks for investors include the company's persistent operating losses, as evidenced by the $38.2 million net loss in Q2 2025, and the significant accumulated deficit of $1.1 billion, which suggests a high likelihood of future capital raises and potential dilution.
How does Butterfly Network's Q2 2025 performance compare to the first half of 2024?
For the six months ended June 30, 2025, Butterfly Network's total revenue was $37.9 million, a decline from $40.1 million in the first half of 2024.
What is the strategic outlook for Butterfly Network given these results?
The strategic outlook for Butterfly Network continues to focus on expanding its ultrasound technology, but the company must address its ongoing unprofitability and declining product sales to achieve sustainable growth and investor confidence.
Is Butterfly Network generating positive cash flow from operations?
The filing indicates continued net losses, suggesting Butterfly Network is not generating positive cash flow from operations and likely relies on financing activities to sustain its business.
What impact could Butterfly Network's financial results have on its competitive position?
Butterfly Network's declining revenue and significant losses could weaken its competitive position against larger, more financially stable medical imaging companies like GE Healthcare and Philips, potentially limiting its ability to invest in R&D and market expansion.
Risk Factors
- Continued Operating Losses [high — financial]: The company reported a net loss of $38.2 million for Q2 2025, a slight improvement from $42.5 million in Q2 2024. However, the accumulated deficit grew to $1.1 billion as of June 30, 2025, underscoring persistent unprofitability.
- Need for Additional Capital [high — financial]: The substantial accumulated deficit of $1.1 billion indicates a significant reliance on external funding to sustain operations. Future profitability is crucial to avoid further dilution or financial distress.
- Revenue Decline in Core Products [medium — market]: Product revenue decreased by 12.8% to $12.3 million in Q2 2025 compared to $14.1 million in the prior year. This decline in the primary revenue stream poses a risk to overall financial health.
- Dependence on Technology Adoption [medium — operational]: Butterfly Network's business model relies heavily on the widespread adoption of its novel ultrasound technology. Slow market penetration or competitive pressures could hinder revenue growth and profitability.
Industry Context
The medical imaging industry, particularly in ultrasound technology, is competitive and driven by innovation. Companies like Butterfly Network aim to disrupt traditional markets with more accessible and portable solutions. However, market adoption is influenced by clinical validation, reimbursement policies, and the established presence of legacy players.
Regulatory Implications
As a medical device company, Butterfly Network is subject to stringent regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance is critical. Any delays or failures in regulatory processes can significantly impact product launches and market access.
What Investors Should Do
- Monitor progress towards profitability
- Assess market adoption and competitive landscape
- Evaluate future capital needs
Glossary
- Accumulated Deficit
- The total cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total amount of money a company has lost over its lifetime. (Indicates Butterfly Network's ongoing unprofitability, with the deficit reaching $1.1 billion as of June 30, 2025.)
- Product Revenue
- Revenue generated from the sale of physical goods or products. For Butterfly Network, this primarily refers to their ultrasound devices. (Represents the core sales segment, which saw a decline of 12.8% in Q2 2025.)
- Software and Other Services Revenue
- Revenue derived from software subscriptions, licensing, and other related services. For Butterfly Network, this includes revenue from their software platform and services. (This segment showed modest growth of 6.3% in Q2 2025, indicating a potential shift towards recurring revenue.)
Year-Over-Year Comparison
Compared to the prior year's second quarter, Butterfly Network reported a 6.8% decrease in total revenue, driven by a significant 12.8% drop in product revenue. While software and other services revenue saw a modest 6.3% increase, it was not enough to offset the decline in core product sales. The net loss improved slightly, but the accumulated deficit continued to grow, indicating persistent financial challenges. No new significant risks were highlighted in this filing compared to the previous period, with the primary concerns remaining operational and financial.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 1, 2025 regarding Butterfly Network, Inc. (BFLY).